- You can view the full AstraZeneca Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.